banner2

Getting started
Ethyl 4-Oxocyclohexanecarboxylate CAS 17159-79-4

Ethyl 4-Oxocyclohexanecarboxylate CAS 17159-79-4 - China Manufacturers, Suppliers, Factory

Ethyl 4-Oxocyclohexanecarboxylate CAS 17159-79-4, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

Ethyl 4-Oxocyclohexanecarboxylate CAS 17159-79-4 Purity 99.0 (GC) Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Ethyl 4-Oxocyclohexanecarboxylate CAS 17159-79-4 Purity >99.0% (GC)
Read More

N-Cbz-N-Methyl-L-Isoleucine CAS 42417-66-3 Purity ≥98.0% (HPLC)

DL-Proline Methyl Ester Hydrochloride CAS 79397-50-5 Assay ≥98.0% (TLC)

D-Phenylalanine Methyl Ester Hydrochloride CAS 13033-84-6 Assay ≥98.0% (HPLC)

D-Alanine Ethyl Ester Hydrochloride CAS 6331-09-5 Assay ≥98.0% (HPLC)

D-Glutamic Acid Dimethyl Ester Hydrochloride CAS 27025-25-8 Assay ≥99.0% (Titration)

D-Glutamic Acid Diethyl Ester Hydrochloride CAS 1001-19-0 Assay ≥99.0% (Titration)

banner4

Top Selling Products

Related Blog
Reviews

Method Of Analyzing Palladium Content In Palladium Catalysts

1. Abstract Enrichment palladium of palladium catalysts by pyrometallurgy, then dissolve the palladium in admixture acid, the liquid is analyzed by AAS. 2. Reagent 2.1 Hydrochloric acid(ρ1.19g/ml) ...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021)-Shanghai Ruifu Chemical Co., Ltd. participated in the exhibition

The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021) was held on September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. Adhering to...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...

2022.12.26 17:42:38
2022.11.20 02:20:20
2022.06.03 13:33:33
2022.04.15 04:57:31
2022.02.18 13:31:00
2021.11.13 00:52:31

related search